Telbivudine Production Cost Reports

The report provides a detailed analysis essential for establishing a telbivudine production plant. It encompasses all critical aspects necessary for telbivudine production, including the cost of telbivudine production, telbivudine plant cost, telbivudine production costs, and the overall telbivudine production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a telbivudine production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Telbivudine is an oral nucleoside analogue antiviral that inhibits hepatitis B virus (HBV) DNA polymerase. This suppresses viral replication in adults with chronic hepatitis B showing active viral load, elevated liver enzymes (ALT/AST), or histological damage. It is mainly utilised in HBeAg-positive or negative cases with compensated liver disease. It is dosed at 600 mg daily, outperforming lamivudine in viral suppression, ALT normalisation, and HBeAg seroconversion while showing lower early resistance in treatment-naïve patients. It reduces liver inflammation and prevents progression to cirrhosis or cancer when used long-term or in combination. Its common side effects include fatigue, headache, cough, diarrhoea, nausea, abdominal pain, sore throat, fever, rash, etc.

The market for telbivudine is driven by high chronic hepatitis B cases globally. The rising awareness, better diagnostics and government screening programs contribute to its demand. The need for effective oral antivirals that suppress viral load and prevent liver complications like cirrhosis contributes to its market growth.

Its favourable efficacy in treatment-naïve patients, lower resistance rates versus older drugs, and integration into combination therapies boost its market. The competitive generic pricing after patent expiry and reliable API supply from manufacturers affects industrial telbivudine procurement. Also, reimbursement support in high-burden areas, R&D for improved formulations, and challenges from newer rivals like tenofovir or entecavir impact its sourcing.

Raw Material for Telbivudine Production

According to the telbivudine production plant project report, the key raw materials used in the production of telbivudine include 2-deoxy-3,5-di-O-p-chlorobenzoyl-L-thymidine, methanol, and sodium methoxide.

Production Process of Telbivudine

The extensive telbivudine production cost report consists of the following major industrial production process:

1. From 2-deoxy-3,5-di-O-p-chlorobenzoyl-L-thymidine: The production process of telbivudine starts by dissolving 2-deoxy-3,5-di-O-p-chlorobenzoyl-L-thymidine in methanol. To this, sodium methoxide is added in methanol to remove the p-chlorobenzoyl protecting groups and generate telbivudine in solution. After the reaction, concentrated hydrochloric acid is added to neutralise the base and adjust the pH. The solvent is evaporated to give a crude solid, and this solid is recrystallised by slurrying in hot acetone, followed by cooling, filtration, washing, and drying to obtain telbivudine.

Telbivudine is a synthetic thymidine β-L-nucleoside analogue antiviral with a molecular formula of C10H14N2O5 and a molecular weight of 242.23 g/mol. It appears as a white to off-white crystalline solid that has a melting point between 186 and 190 degree Celsius. It features a thymine base linked to a modified 2-deoxy-L-ribofuranose sugar, showing low water solubility (~1-10 mg/mL) and slight DMSO solubility. It has 3 hydrogen bond donors and 5 acceptors, a polar surface area of 99.1 Ų, and moderate hydrophilicity (XLogP3 -1.2) supporting oral bioavailability. It is stable as the L-enantiomer and inhibits HBV DNA polymerase after intracellular phosphorylation to the triphosphate form.